Behavioral effects of multiple-dose oxytocin treatment in autism: a randomized, placebo-controlled trial with long-term follow-up

Table 1 Participant characteristics

	Oxytocin	Placebo	T value	p value
Number of participants	22	18
Age	25.00 ± 4.86	24.00 ± 5.55	0.62	0.54
IQ
Total IQ	102.27 ± 12.45	104.61 ± 21.59	-0.43	0.67
VIQ	105.57 ± 9.27	108.72 ± 16.83	-0.74	0.47
PIQ	104.76 ± 18.35	102.39 ± 22.90	0.36	0.72
ADOS(2)
Total	7.18 ± 4.22	8.06 ± 4.26	-0.65	0.52
Communication	2.05 ± 1.40	2.39 ± 1.54	-0.74	0.46
Social interaction	4.82 ± 3.50	5.67 ± 3.33	-0.78	0.44
Use of psychostimulant medication	6	2
Comorbidity	8	2

Data are shown as mean ± standard deviation. IQ intelligence quotient, VIQ verbal IQ, PIQ performance IQ, ADOS(2) Autism Diagnostic Observation Schedule(2). Detailed information on medication use and comorbidities is provided in Additional file 1: Table S1. Note that for one participant of the OT group only total IQ information was available, but not VIQ or PIQ, so that the mean (± standard deviation) information of the VIQ and PIQ of the OT group are based on data from 21 participants

ISSN: 2040-2392